Sunderstorm Expands Global KANHA Footprint With New European and Australian Partnerships

California-based Sunderstorm is accelerating its international strategy for its KANHA brand with a new EU‑GMP manufacturing partnership in North Macedonia and expanded distribution alliances across Europe and Australia. 

The company announced this week a collaboration with New Garden Pharma, a licensed manufacturer in North Macedonia, to produce pharmaceutical‑grade edibles for Europe and Australia while also developing new product formats and commercializing premium flower. Sunderstorm is also working with California’s Medical GmbH in Germany, FuGu Holdings in Australia, and Grow Group UK in the United Kingdom as part of its broader push into global medical markets.

“KANHA is becoming one of the first truly global cannabis brands by entering some of the world’s most advanced and highly regulated medical markets,” Cameron Clarke, co‑founder and CEO of Sunderstorm, said in a statement from the company. “For more than a decade, we’ve built KANHA into a top‑tier brand in the United States, and over the past three years, we’ve laid the foundation for a fully integrated international supply chain.”

“Through our EU‑GMP partnership with New Garden Pharma and our distribution partners across Europe and Australia, we can now deliver pharmaceutical-grade KANHA products that meet the most stringent global standards,” he continued. “This expansion marks a pivotal step in our evolution from a leading U.S. cannabis company to a global wellness platform serving patients across four continents.”

New Garden Pharma is a vertically integrated European medical cannabis manufacturer operating in accordance with EU‑GMP standards. Grow Group UK is a licensed importer and manufacturer serving physicians and patients across the United Kingdom. California’s Medical GmbH is a German pharmaceutical distributor specializing in EU‑GMP cannabis products, while FuGu Holdings is an Australian company focused on rare and exclusive cultivars sourced from artisan growers.

“Bringing KANHA to Europe through New Garden Pharma’s EU‑GMP manufacturing platform marks an important step in expanding patient access to trusted, precisely formulated cannabis products,” said Alexey Brylev, CEO of New Garden Group.

KANHA is one of the top‑selling edible brands in the United States and began its global expansion in Thailand in 2023. The brand now has distribution across Europe, Japan, and Australia, supported by a supply chain designed to meet the regulatory demands of medical markets. With Europe and Asia‑Pacific projected to grow into multibillion‑dollar medical cannabis regions over the next decade, Sunderstorm is positioning KANHA to serve patients and consumers as access expands.

Clarke on Quality, Consistency, and Global Strategy

As KANHA moves deeper into regulated medical markets, the company’s ability to maintain uniform quality across continents becomes a defining part of its strategy. Clarke said the brand’s approach to manufacturing is built on direct control rather than licensing models that hand off production to third parties. 

“Everything we do rolls up into building a brand people can trust. Quality control is non‑negotiable for us,” Clarke writes in a written interview with IgniteIt. “As we expand internationally, we do not license and walk away. We build fully integrated partnerships rooted in our own rigorous manufacturing standards and strict compliance. We do not allow anyone else to manufacture our products.”

He added that the operational backbone supporting this expansion is designed to eliminate variability across markets. Clarke said the company’s systems and oversight structure enable KANHA to scale without diluting its core formulations or consumer expectations. 

“Consistency comes down to systems, processes, staff training, and oversight,” he explains. “And we manage all this from HQ in Los Angeles. Our global supply chain is intentionally structured to protect formulation integrity while meeting local regulatory requirements.”

As KANHA enters medical markets with stricter rules and more specialized patient needs, Clarke said the company adapts thoughtfully without altering the science behind its products. He noted that regulatory frameworks often dictate packaging, dosage formats, and allowable ingredients, but the brand’s formulation philosophy remains intact. 

“We tailor products to meet regulatory frameworks and patient needs in each market, but what remains constant is our focus on predictable onset, consistent dosing, and delivering reliable experiences patients and consumers can trust,” says Clarke.

Even as KANHA expands globally, North America remains a priority for the company. Clarke said the brand is widening its category footprint while also using acquisitions to strengthen its position in competitive markets like California. 

“We are expanding our vape category into new markets and, in California, our acquisition of Lime has expanded our offering into the preroll category,” he writes. “At the same time, we have broadened accessibility through hemp‑derived cannabinoid products available online. We are convinced hemp is here to stay and are focusing our energy in markets where we are not currently licensed.”